psoriatic arthritis
FDA Expands Indication for Abatacept to Treat Juvenile Psoriatic Arthritis
The FDA expanded the indication for abatacept for the treatment of patients 24 months of age and older with active ...
NOVEMBER 1, 2023
FDA Grants Second Indication for Skyrizi
Risankizumab-rzaa is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 ...
JANUARY 24, 2022
FDA Approves Rinvoq for Active Psoriatic Arthritis
The FDA has approved upadacitinib (Rinvoq, Abbvie) for the treatment of adults with active psoriatic arthritis who ...
DECEMBER 15, 2021
Cosentyx Improves Symptoms, QOL for Children With Psoriasis
Plaque psoriasis is the most common type of psoriasis in children.
MAY 7, 2021
FDA Approves Hadlima Biosimilar for RA, Other Inflammatory Condition
Hadlima was approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic ...
AUGUST 27, 2019
Secukinumab Rx Improves Quality-of-Life Measurements as Early as 4 Weeks
Findings suggest that helping patients feel better through improved quality of life and ability to function ...
JANUARY 28, 2019
